Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and…

Conclusion: Cancer patients who received cetuximab have a substantial risk of developing high-grade skin rash. The risk may be particularly increased in patients with CRC. Further studies are strongly recommended for the prevention and treatment of high-grade skin rash

See the rest here:
Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and…

Related posts:

1. Rash After Cetuximab Is Indicator of Clinical Benefit An acne-like rash among patients with non-small-cell lung cancer undergoing...
2. First-cycle rash in patients receiving cetuximab-based treatment for NSCLC associated with improved outcome? Source: Lancet Oncology Area: News According to a subgroup analysis...
3. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer Conclusion During the treatment with EGFRI, it is necessary to...
4. Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a… This study was to summarize our experiences in treating NSCLC...
5. Patients Treated for Severe Acne Have Higher Suicide Risk Individuals treated with isotretinoin for severe acne are at an...

Leave a comment

Name (required)

E-mail (required)

URI

Your Message